UNSPSC 51384623: Bendazac lysine dihydrate

This classification denotes the lysine-dihydrate form of a nonsteroidal antiinflammatory drug with the molecular formula C16H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G4AG71204O, chemically known as acetic acid, ((1-(phenylmethyl)-1h-indazol-3-yl)oxy)- but more generally known as bendazac, which bears US NIH Compound Identifier 2313. Bendazac most often comes in base, lysine, methyl ester, and sodium forms.

UNSPSC 51384623 Bendazac lysine dihydrate is a Commodity code that in practice encompasses a much broader range of pharmaceutical and over-the-counter products than its nominal title suggests. State and local procurement activity under this code reflects generic multi-source pharmaceuticals, naloxone and drug-deactivation systems, and OTC products distributed through cooperative purchasing agreements and direct health-system procurement. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The mix reflects both direct-purchase solicitations for specific therapeutic agents and aggregated commodity procurement mechanisms that serve multiple jurisdictions through authorized wholesale channels.

Recent activity concentrates in Florida and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option; responses were due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription-fulfillment capabilities, signaling emerging interest in alternative distribution models beyond traditional pharmacy benefit managers and group purchasing organizations. The code shows active engagement across health-system procurement, cooperative purchasing vehicles, and exploratory market-intelligence gathering by state-level health agencies.